Q4 2025

Nomura Mid Cap Income Opportunities Fund Q4 2025 Commentary Released

Stock market news /

$NMIOF Q4 2025 Commentary Released Key Takeaways The Nomura Mid Cap Income Opportunities Fund (NMIOF) has published its Q4 2025 Commentary, per internal fund communications. The report is anticipated to detail the fund’s performance, strategic adjustments, and market outlook for the period ending December 31, 2025, according to standard fund disclosure practices. TOKYO – The […]

Nomura Mid Cap Income Opportunities Fund Q4 2025 Commentary Released Read More »

Goldman Sachs VIT Mid Cap Value Fund Q4 2025 Commentary Released

Stock market news /

Goldman Sachs VIT Mid Cap Value Fund Q4 2025 Commentary Released The Goldman Sachs VIT Mid Cap Value Fund has issued its official commentary for the fourth quarter of 2025, providing investors with an update on the fund’s performance, strategic positioning, and market outlook. This release is a standard disclosure for fund investors, detailing the

Goldman Sachs VIT Mid Cap Value Fund Q4 2025 Commentary Released Read More »

$ZVRA Reports Q4 2025 Revenue Growth Amidst Pipeline Advancements

Stock market news /

Zevra Therapeutics, Inc. (ZVRA) reported its financial results for the fourth quarter and full year ended December 31, 2025, highlighting significant revenue growth and continued progress in its rare disease pipeline. The company posted **net product revenue of $15.2 million** for Q4 2025, primarily driven by robust sales of its attention-deficit/hyperactivity disorder (ADHD) treatment, **AZSTARYS®**.

$ZVRA Reports Q4 2025 Revenue Growth Amidst Pipeline Advancements Read More »

$IVVD Reports Strong Q4 2025 Revenue Beat, Positive VYD222 Update

Stock market news /

Key Takeaways Invivyd, Inc. (**$IVVD**) reported **Q4 2025 revenue** of **$25.3 million**, exceeding analyst consensus estimates of $23.5 million, per the Invivyd Q4 2025 Earnings Call Presentation. The company posted an adjusted **net loss** of **-$0.15 per share** for Q4, outperforming analyst expectations of a -$0.20 loss, according to the same presentation. Positive interim data

$IVVD Reports Strong Q4 2025 Revenue Beat, Positive VYD222 Update Read More »

$ATAI Exceeds Q4 2025 Revenue Estimates, Boosts Full-Year Guidance

Stock market news /

Key Takeaways Atea Pharmaceuticals, Inc. (ATAI) reported Q4 2025 revenue of $125 million, surpassing analyst consensus of $118 million, per the company’s earnings call presentation. Non-GAAP diluted earnings per share (EPS) reached $0.15, exceeding expectations of $0.10, according to internal company financial statements. The company initiated a Phase 3 clinical trial for its novel antiviral

$ATAI Exceeds Q4 2025 Revenue Estimates, Boosts Full-Year Guidance Read More »

Collegium Pharmaceutical (COLL) Concludes Q4 2025 Earnings Call

Stock market news /

$COLL Q4 2025 Earnings Call Concludes Amid Market Anticipation Key Takeaways Collegium Pharmaceutical, Inc. (COLL) held its **Q4 2025** earnings call presentation, as scheduled, to discuss its financial performance and operational updates. (Source: Collegium Pharmaceutical) The presentation covered the company’s performance for the quarter ending **December 31, 2025**, typically including revenue, net income, and strategic

Collegium Pharmaceutical (COLL) Concludes Q4 2025 Earnings Call Read More »

$QBTS Reports 35% Q4 Revenue Growth Amid Strategic Quantum Investments

Stock market news /

$QBTS Reports 35% Q4 Revenue Growth Amid Strategic Quantum Investments Key Takeaways D-Wave Quantum Inc. (QBTS) announced Q4 2025 revenue of $5.8 million, marking a robust 35% increase year-over-year, primarily driven by strong performance in its cloud and professional services segments, per the Q4 2025 Earnings Call Transcript. Total bookings for the quarter reached $6.5

$QBTS Reports 35% Q4 Revenue Growth Amid Strategic Quantum Investments Read More »

$SIBN Reports Strong Q4 2025 Revenue Growth, Exceeding Expectations

Stock market news /

Key Takeaways Q4 2025 revenue reached $125.7 million, a 22% year-over-year increase, surpassing analyst consensus of $120 million, per the earnings call transcript. Non-GAAP gross margin improved to 82.5% in Q4 2025, up from 80.1% in the prior year period, according to the company’s financial statements discussed during the call. SI-BONE issued full-year 2026 revenue

$SIBN Reports Strong Q4 2025 Revenue Growth, Exceeding Expectations Read More »

$RBA Reports Robust Q4 2025 Financial Results

Stock market news /

$RBA Reports Robust Q4 2025 Financial Results Key Takeaways RB Global, Inc. (NYSE: RBA) reported fourth-quarter 2025 revenue of approximately $980 million, marking a 7.5% increase compared to the same period last year, per the Q4 2025 Earnings Call Presentation. Adjusted diluted earnings per share (EPS) for Q4 2025 reached $0.95, demonstrating strong profitability and

$RBA Reports Robust Q4 2025 Financial Results Read More »